The FDA has upgraded the thyroid medication recall to its highest risk level.

The FDA classified the recall of one lot of Vitruvias Therapeutics Thyroid Tablets, USP 30 mg as Class I, the agency's highest-risk recall category.

Vitruvias Therapeutics, Inc Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency

Thyroid medication recall upgraded to FDA's highest risk level

FDA elevates thyroid tablet recall to most serious level

Thyroid medication recall elevated to FDA's highest risk level

fda upgraded thyroid medication recall highest risk level

Trending Now - Google Trends

Health & Medicine

Science & Environment

The product is being recalled because testing confirmed the potential for the product to be superpotent.

On Tuesday, the recall was upgraded to Class I, "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death."

This week, the FDA reclassified the recall of the product to Class I.

A thyroid medication that was initially recalled in August due to concerns about it being "superpotent" has now been classified by the U.S. Food and Drug Administration (FDA) as a Class I recall, indicating the highest level of risk.

The FDA has upgraded the thyroid medication recall to its highest risk level.

💬Discussion